Related Experiment Video
Updated: Sep 27, 2025
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
Panagiotis Baliakas1,2, Blanca Espinet3,4, Clemens Mellink5
1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Cytogenetic analysis, including chromosome banding analysis (CBA) and chromosome microarray analysis (CMA), is valuable in chronic lymphocytic leukemia (CLL) for identifying prognostic biomarkers. However, standardized methods and clear clinical interpretation guidelines are still needed for both CBA and CMA in CLL management.
Area of Science:
- Hematology
- Oncology
- Clinical Genetics
Background:
- Cytogenetic analysis is crucial in chronic lymphocytic leukemia (CLL) for identifying prognostic biomarkers, such as complex karyotypes.
- Current recommendations for chromosome banding analysis (CBA) and chromosome microarray analysis (CMA) methodology and clinical interpretation in CLL are lacking.
Purpose of the Study:
- To present the European Research Initiative on CLL (ERIC) Cytogenetic Steering Scientific Committee's consensus on CBA/CMA methodology and interpretation in CLL.
- To discuss the clinical relevance and utility of CBA and CMA in managing CLL patients.
Main Methods:
- Consensus development by the ERIC Cytogenetic Steering Scientific Committee.
- Review of methodological issues and clinical interpretation of CBA and CMA in the context of CLL.
Main Results:
- ERIC considers CBA standardized and feasible for CLL if specific standards, including novel mitogens and accurate interpretation, are met.
- CMA is also standardized, but robust clinical utility data in CLL are scarce.
Conclusions:
- Cytogenetic analysis is not yet sufficiently mature to guide CLL treatment decisions.
- ERIC advocates for the widespread use of CBA and CMA in clinical trials to gather evidence for refining risk stratification and improving CLL patient management.
